Sight Sciences, Inc. (NASDAQ:SGHT) Insider Sells $122,471.91 in Stock

Sight Sciences, Inc. (NASDAQ:SGHT - Get Free Report) insider Matthew Link sold 21,831 shares of the stock in a transaction dated Monday, October 21st. The stock was sold at an average price of $5.61, for a total transaction of $122,471.91. Following the transaction, the insider now owns 663,550 shares in the company, valued at approximately $3,722,515.50. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Matthew Link also recently made the following trade(s):

• On Friday, October 18th, Matthew Link sold 20,487 shares of Sight Sciences stock. The stock was sold at an average price of $5.98, for a total transaction of $122,512.26.
• On Wednesday, October 16th, Matthew Link sold 20,734 shares of Sight Sciences stock. The stock was sold at an average price of $5.91, for a total transaction of $122,537.94.

Sight Sciences Stock Performance

SGHT traded down $0.45 during trading on Monday, reaching $5.52. 225,198 shares of the company's stock were exchanged, compared to its average volume of 193,711. Sight Sciences, Inc. has a 1 year low of $1.04 and a 1 year high of $8.45. The company has a debt-to-equity ratio of 0.33, a current ratio of 11.01 and a quick ratio of 10.50. The stock has a market capitalization of $277.71 million, a P/E ratio of -5.16 and a beta of 2.71. The company's fifty day simple moving average is $6.31 and its 200-day simple moving average is $6.30.

Sight Sciences (NASDAQ:SGHT - Get Free Report) last posted its quarterly earnings results on Thursday, August 1st. The company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.31) by $0.06. Sight Sciences had a negative net margin of 65.90% and a negative return on equity of 45.68%. The company had revenue of $21.37 million during the quarter, compared to analyst estimates of $21.32 million. During the same period last year, the firm posted ($0.30) EPS. As a group, research analysts predict that Sight Sciences, Inc. will post -1 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. Needham & Company LLC restated a "hold" rating on shares of Sight Sciences in a report on Friday, August 2nd. Morgan Stanley lifted their target price on shares of Sight Sciences from $5.40 to $6.50 and gave the stock an "equal weight" rating in a research note on Monday, July 15th. Citigroup lifted their target price on shares of Sight Sciences from $6.00 to $6.50 and gave the stock a "neutral" rating in a research note on Wednesday, July 10th. Finally, Lake Street Capital started coverage on shares of Sight Sciences in a research note on Wednesday, August 21st. They issued a "buy" rating and a $10.00 target price for the company. Four equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat, Sight Sciences currently has a consensus rating of "Hold" and a consensus price target of $7.25.

Hedge Funds Weigh In On Sight Sciences

Several institutional investors have recently made changes to their positions in the company. SG Americas Securities LLC purchased a new position in shares of Sight Sciences during the 3rd quarter valued at approximately $75,000. B. Riley Wealth Advisors Inc. purchased a new stake in Sight Sciences in the 2nd quarter worth $1,234,000. Long Focus Capital Management LLC increased its holdings in Sight Sciences by 86.9% in the 2nd quarter. Long Focus Capital Management LLC now owns 560,594 shares of the company's stock worth $3,739,000 after acquiring an additional 260,594 shares in the last quarter. The Manufacturers Life Insurance Company purchased a new stake in Sight Sciences in the 2nd quarter worth $95,000. Finally, American Century Companies Inc. increased its holdings in Sight Sciences by 31.1% in the 2nd quarter. American Century Companies Inc. now owns 35,948 shares of the company's stock worth $240,000 after acquiring an additional 8,527 shares in the last quarter. 55.51% of the stock is owned by hedge funds and other institutional investors.

Sight Sciences Company Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.